Dallas, Texas-based Vaxxinity, under the direction of CEO Mei Mei Hu, JD and Chief Medical Officer Ulo Palm, uses synthetic peptides to mimic and optimally combine biological epitopes to selectively activate the immune system and overcome â€śimmune toleranceâ€ť, or the bodyâ€™s tendency to avoid attacking molecules within your own body. Traditional vaccine technologies have to date fallen short in attempts to achieve this due to insufficient responses and side effects. The platform has been scientifically validated, with billions of doses commercialized in animal health, and 6 human clinical trials successfully completed. UB-312 targets toxic forms of aggregated Î±-synuclein in the brain to fight Parkinsonâ€™s and other synucleinopathies, such as dementia with Lewy Body (â€śDLBâ€ť) and multiple system atrophy (â€śMSAâ€ť). The first part of a Phase 1 trial in healthy volunteers has shown UB-312 to be well tolerated, with no significant safety findings, and immunogenic, with a high responder rate and antibodies that cross the blood-brain barrier (â€śBBBâ€ť).